|
|
KML-B |
|
Vaxjo ID |
217 |
|
Vaccine Adjuvant Name |
KML-B |
|
Adjuvant VO ID |
VO_0005642
|
|
Description |
KML-B is the B-chain of Korean mistletoe lectin (KML), which binds to cell surfaces. It acts as a novel TLR4 agonist and exhibits potent immunomodulatory properties by enhancing dendritic cell maturation. |
|
Stage of Development |
Research |
|
Host Species for Testing |
None |
|
Components |
Korean mistletoe lectin (KML) is composed of A and B sub-chains |
|
Structure |
It is described as a "B-chain" of Korean mistletoe lectin. |
|
Function |
This study evaluated the immunoadjuvant and cytotoxic effects of KML B-chain (KML-B) using bone marrow-derived dendritic cells (BMDCs). KML-B was non-cytotoxic and promoted BMDC maturation, evidenced by increased expression of co-stimulatory molecules (CD40, CD80, CD86, MHC II), cytokine secretion (IL-1β, IL-6, IL-12p70, TNF-α), enhanced antigen uptake, and CCR7 expression. These effects were dependent on TLR4. Additionally, KML-B-matured BMDCs drove naïve CD4⁺ T cells toward Th1 differentiation. These findings demonstrate KML-B’s potent immunomodulatory activity and support its potential as a dendritic cell-based cancer immunotherapy and adjuvant. |
|
Safety |
KML-B was found to be non-cytotoxic to bone marrow-derived dendritic cells (BMDCs). |
| References |
Kim et al., 2014: Kim JJ, Hwang YH, Kang KY, Kim I, Kim JB, Park JH, Yoo YC, Yee ST. Enhanced dendritic cell maturation by the B-chain of Korean mistletoe lectin (KML-B), a novel TLR4 agonist. International immunopharmacology. 2014; 21(2); 309-319. [PubMed: 24859056].
|
|
